

Coagulation Studies

A previously healthy 68-year-old woman presents with spontaneous bleed into her psoas muscle. The results of coagulation tests are shown below. Which of the following best accounts for these results?

	Value	Reference range
Activated Partial Thromboplastin Time (APTT)	79	26 -38
APTT correction (immediate mix)	38	26 -38
APTT correction (2-h incubation)	79	26 -38
International normalised ratio (INR)	1.1	0.9 -1.2
Fibrinogen (g/L)	3.2	2.0 -4.0

- A. Von Willebrand Disease
- B. Disseminated intravascular coagulation (DIC)
- C. Acquired Factor VIII inhibitor
- D. Chronic liver disease
- E. Haemophilia B

Acquired Factor VIII inhibitor

The sudden appearance of a large haemorrhage into the muscle in an elderly person with an elevated activated partial thromboplastin time (APTT) should raise the suspicion of an acquired factor VIII inhibitor (Franchini and Lippi, 2008). Patients often present with large haematomas, extensile ecchymoses or severe mucosal bleeding, including epistaxis, gastrointestinal bleeding and gross haematuria. Spontaneous haemarthroses are unusual. The cause is usually circulating autoantibodies directed against functional epitopes of factor VIII, causing neutralisation and/or its accelerated clearance

from the plasma. There are associations with post-parturition, rheumatoid arthritis, systemic lupus erythematosus and underlying malignancies.

The APTT assay is a reliable screening test for factor VIII inhibitor detection as it is typically prolonged when factor VII activity decreases to 45% of the mean normal level or less. Furthermore, mixing studies with patient plasma and normal plasma do not normalise the APTT. Weak autoantibodies, however, may not prolong the APTT unless the mixture is incubated for at least 1 or 2h at 37°C.

As a result, while mixing studies may show initial normalisation of APTT, repeat Studies after 1-2h of incubation typically shows that the APTT is prolonged again.

Although von Willebrand disease may be diagnosed at an older age and is associated with prolonged APTT with normal PT and INR, there is usually personal and family history of bleeding. In coagulopathy due to chronic liver disease there will usually be an elevated INR and APTT. Haemophilia B, which usually presents a early age with characteristic spontaneous haemarthroses, is associated with prolonged APTT with normal PT and INR. In acute disseminated intravascular coagulopathy (DIC) both APTT and INR are prolonged, while the fibrinogen levels are low due to rapid consumption


<https://doi.org/10.1182/blood-2008-03-143586>

Complete Blood Examination

A 32-year-old woman presents to the emergency department with an 8-h history of severe right upper quadrant pain. An abdominal ultrasound reveals several mobile gallstones and gallbladder wall thickening, which is consistent with acute cholecystitis. The liver is unremarkable but the spleen measures 14cm. The cholecystitis improves with conservative management. On further questioning, she tells you that her father had his spleen removed. The results of investigations and the blood film are shown below. Which one of the following tests is the most appropriate next investigation?

	Value	Reference range
Haemoglobin (g/L)	111	115 -155
Mean corpuscular volume (fL)	101	80 -98

	Value	Reference range
White blood cells (L)	8.1×10^9	$4.0 - 11.0 \times 10^9$
Platelet count (L)	190×10^9	$150 - 400 \times 10^9$
Bilirubin ($\mu\text{mol/L}$)	27	2 - 24



- A. Autoimmune profile
- B. Bone marrow biopsy
- C. Coombs test
- D. Osmotic fragility test
- E. Haemoglobin electrophoresis

Osmotic fragility test

This patient's history is strongly suggestive of hereditary spherocytosis, which is associated with increased haemolysis and subsequent raised risk of gallstones seen here. Spherocytosis is caused by inherited defects in the membrane of red blood cells that reduce cell deformability. This leads to cells being removed by the spleen, which causes progressive splenic enlargement.

Disease is mild in 20-30% of patients. As in this case, hereditary spherocytosis can present later in life. However, 60-70% of patients have more severe anaemia and splenomegaly, which leads to presentation in childhood. Hereditary spherocytosis is most commonly associated with dominant inheritance (75%). Mutations of genes encoding ankyrin, spectrin, or Band 3 red cell proteins account for most cases.

The diagnosis of hereditary spherocytosis is usually made on clinical grounds, based upon the presence of spherocytes on blood film. A number of tests are available for identifying individuals with hereditary spherocytosis:

- Osmotic fragility testing
- Ektacytometry
- Acidified glycerol lysis test (AGLT)
- Cryohaemolysis test
- Eosin-5-maleimide binding test (EMA binding test).

A 60-year-old man has recently been diagnosed with B-cell non-Hodgkin lymphoma. He is waiting for chemotherapy to commence in 2 days. He suddenly develops headache, confusion, visual deterioration and epistaxis. Fundoscopy reveals retinal hemorrhages. Which one of the following investigations should be included in the evaluation?

- A. Complement levels
 - B. C-reactive protein
 - C. Plasma electrophoresis
 - D. Serum free light chains
 - E. Serum viscosity
-

Serum Viscosity

This patient's presentation is suspicious for hyperviscosity syndrome in the setting of a lymphoproliferative disorder and cryoglobulinaemia is a possible cause. B-cell lymphoproliferative diseases are the major cause of cryoglobulinaemia associated with malignancy. Type I cryoglobulinaemia is reported predominantly in patients with Waldenström macroglobulinaemia, multiple myeloma, or chronic lymphocytic leukaemia. Mixed cryoglobulinaemias occur mainly in B-cell lymphomas.

Two major mechanisms are involved to a varying extent in the different types of cryoglobulinaemia: cryoglobulin precipitation in the microcirculation, and vascular immune complex-mediated inflammation. Vascular occlusion is more frequent in type I cryoglobulinaemia, which is usually accompanied by high cryoglobulin concentrations, and can be associated with hyperviscosity syndrome and cold-induced acral necrosis. Immune complex-mediated vasculitis is more frequent in mixed cryoglobulinaemias, particularly type II, in which the monoclonal IgM component generates large immune complexes with IgG and complement fractions. Hyperviscosity syndrome develops mainly in patients with type I cryoglobulinaemia associated with haematological malignancies, and is uncommon in patients with mixed cryoglobulinaemia (<3%). The key symptoms are neurological (headache, confusion), ocular (blurred vision, visual loss) and ear and nose (epistaxis, hearing loss). The physical examination should include fundoscopy to exclude hyperviscosity-related retinal changes, including haemorrhages. In patients in whom hyperviscosity syndrome is suspected, serum viscosity should be measured. Patients usually become symptomatic at viscosity measurements greater than 4.0 cP, but some patients are symptomatic with lower viscosities. Symptomatic hyperviscosity requires urgent treatment with plasma exchange.

Low complement levels (particularly C4) and raised titres of serum rheumatoid factor are commonly observed in mixed cryoglobulinaemias and can correlate with clinical symptoms. Cryoglobulin detection can be difficult given the requirement to maintain blood at 37°C prior to analysis. Hepatitis C (HCV) testing (antibodies and serum HCV-RNA detection) is important in patients with mixed cryoglobulinaemia. Testing for other viruses (hepatitis B virus, HIV) and autoimmune diseases (anti-nuclear, anti-DNA, anti-Ro/La, anti-citrullinated antibodies) is recommended, even in patients known to have HCV.

[https://doi.org/10.1016/S0140-6736\(11\)60242-0](https://doi.org/10.1016/S0140-6736(11)60242-0)

A 52-year-old woman who had an ischemic stroke 12 months ago has residual neurological deficits was referred for evaluation of recurrent episodic proximal deep venous thrombosis (DV) of the lower limbs in the last 10 months. The results of investigations are shown below. A bone marrow biopsy showed mild hyperplasia of erythroid bone marrow. Urine dipstick for blood was +++. What is the most likely diagnosis?

	Value	Reference range
Haemoglobin (g/l)	82	115 -155
Mean corpuscular volume (fL)	98	80 -98
Mean corpuscular haemoglobin (pg)	31	27-33
White blood cells (cells/l)	4.0	4.0-11.0 × 10
Platelet count (cells/l)	93 × 10	150-400 × 10
Reticulocytes (%)	5.4	0.5 -1.5
Total bilirubin (μmol/L)	50	2 -24
Lactate dehydrogenase (U/L)	944	110 -230
Coombs test	Negative	

- A. Anti-thrombin III deficiency
- B. Haemolytic uraemic syndrome
- C. Paroxysmal nocturnal haemoglobinuria
- D. Homocysteinaemia
- E. Protein C deficiency

Paroxysmal Nocturnal Haemoglobinuria

Paroxysmal nocturnal haemoglobinuria (PNH) is a rare haematopoietic stem cell disorder caused by a somatic mutation in a gene known as phosphatidylinositol glycan class A (PIGA) (Brodsky, 2009). It may arise de novo or in the setting of acquired aplastic anaemia. The product of the PIGA gene is required for the biosynthesis of a glycolipid anchor that attaches a class of membrane proteins known as glycosylphosphatidylinositol (GPI)-anchored proteins to the cell surface.

The absence of GP-anchored proteins leads to complement-mediated intravascular haemolysis, because two important complement regulatory proteins (CD55 and CD59) are missing from PNH cells.

Clinical presentations include acute intravascular haemolytic crisis, especially nocturnal, chronic haemolytic anaemia, haemoglobinuria, bone marrow failure and thrombosis. Haemolysis in PNH occurs intravascularly, leading to release of free haemoglobin, a potent nitric oxide scavenger. Depletion of nitric oxide contributes to fatigue, splanchnic spasm, thrombosis and male erectile dysfunction.

In the past, PNH was diagnosed indirectly based upon the sensitivity of PNH red cells to lysis by complement (e.g. Ham test). However, the recognition of a deficiency of GPI-linked proteins in PNH has resulted in the development of flow cytometric methods for diagnosis. Thrombosis, the leading cause of death from PNH, most commonly occurs in abdominal and cerebral veins, but arterial thrombotic episodes can occur. Therapeutic options include bone marrow transplantation and monoclonal antibody therapy with the terminal complement inhibitor, eculizumab. Eculizumab decreases haemolysis in PNH by binding to C5 and blocking the terminal portion of the complement cascade

<https://doi.org/10.1182/blood-2009-03-195966>

A 54-year-old obese woman presents with extensive deep venous thrombosis of her left leg. She has a family history of venous thromboembolism. She was started on low-molecular-weight heparin and warfarin 10mg daily for 2 days. Within 72h, she developed necrotising skin lesions on her thighs without trauma. What underlying condition is most likely to have?

- A. Anti-thrombin III deficiency
- B. Protein S deficiency

- C. Anti-phospholipid syndrome
- D. Protein C deficiency
- E. Homozygous factor V Leiden mutation

--

Protein C Deficiency

Protein C deficiency is associated with recurrent familial thrombosis (Seligsohn and Lubetsky, 2001). It is inherited as an autosomal dominant trait and heterozygotes present with venous thrombotic manifestations. A family history is essential in assessing the association of a patient's deficiency with their risk of thrombosis.

Patients with protein C deficiency are at high risk for warfarin-induced skin necrosis during initiation of therapy. Warfarin-induced skin necrosis occurs in the feet, buttocks, thighs, breasts, upper extremities and genitalia. The lesions usually begin as maculopapular lesions several days after initiation of warfarin and progress into bullous, hemorrhagic and necrotic lesions. The mechanism is thought to be that, following the initiation of warfarin, both protein C antigen and activity levels drop rapidly, compared with levels of other vitamin K-dependent factors, such as factors IX and X and prothrombin. Therefore, administration of warfarin to protein C-deficient individuals causes temporary exaggeration of the balance between pro-coagulant and anticoagulant pathways; that is the early suppressive action of warfarin on protein C may not be counterbalanced by the anticoagulant effect created by the decline in other vitamin K-dependent factors, thereby leading to a relative hypercoagulable state at the start of treatment. This leads to thrombotic occlusions of the microvasculature with resulting necrosis. Protein S deficiency and antithrombin III are rarely associated with warfarin-induced skin necrosis.

Which one of the following is correct concerning atypical haemolytic uraemic syndrome (aHUS)?

- A. It is only an acute disease
 - B. It is predominantly (>80%) a condition affecting children
 - C. It is associated with mutations in genes encoding complement regulatory proteins
 - D. It is due to mutations in the gene encoding ADAMTS13
 - E. Plasma exchange is the only effective treatment
-

Associated with Complement regulatory genes

Atypical haemolytic uraemic syndrome (aHUS) is a genetic, chronic, systemic and potentially life-threatening disease affecting both adults and children. It is associated with mutations in genes encoding both complement regulators (factor H, factor I, membrane cofactor protein and thrombomodulin) and activators (factors B and C3), and autoantibodies against factor H. Diagnosis of aHUS does not require identification of a genetic mutation, as genetic mutations are not identified in 40% of patients with aHUS. Due to permanent genetic mutations, aHUS is an ongoing, lifelong disease of systemic complement-mediated thrombotic microangiopathy (TMA). Approximately half of the patients with aHUS are adults. Renal injury occurs in aHUS but other vital organ systems, including the cardiac and neurological system, are also affected. The related condition thrombotic thrombocytopenic purpura (TTP) results from a deficiency of ADAMTS13, a plasma metalloprotease that cleaves von Willebrand factor.

<https://doi.org/10.1182/asheducation-2011.1.15>

The results of a patient's biochemistry profile after chemotherapy for Burkitt lymphoma are shown below. He was transferred to the intensive care unit for cardiac monitoring and treatment. Which one of the following treatment options should be used to lower uric acid levels?

	Value	Reference range
Potassium (mmol/L)	6.8	3.4-4.5
Phosphate (mmol/L)	2.4	0.70-0.95
Corrected calcium (mmol/l)	1.60	2.10-2.55
Urate (mmol/l)	0.87	0.45-0.60
Creatinine (umol/L)	348	60-120

- A. Aggressive intravenous diuretics
- B. Allopurinol
- C. Rasburicase
- D. Urinary alkalinisation
- E. Prednisolone

Rasburicase

The patient's clinical tumour lysis syndrome is a result of chemotherapy for a highly aggressive mature B-cell lymphoma. As such, the patient developed acute kidney injury, hyperkalaemia, hyperphosphataemia, secondary hypocalcaemia (caused by hyperphosphataemia) and hyperuricaemia. Tumour lysis syndrome (Howard et al., 2011) is seen in patients treated for malignant tumours and extensive metastasis, or with a high rate of proliferation of cancer cells, cancer cell sensitivity to therapy and an intensive cancer treatment regime.

A persistently high uric acid level increases the risk of crystal formation and acute renal injury. Supportive treatment, including intravenous fluids (not diuretics!) and cautious monitoring of the electrolyte imbalance to prevent cardiac dysrhythmias and neuromuscular irritability, should be supplemented with treatment to lower the level of uric acid.

Rasburicase removes uric acid by enzymatically degrading it into allantoin, a highly soluble product that has no known adverse effects. The use of rasburicase can preserve or improve renal function and lower phosphorus levels as a secondary beneficial effect.

Allopurinol is xanthine oxidase inhibitor. It prevents the conversion of hypoxanthine and xanthine into uric acid but does not remove existing uric acid.

Allopurinol has also shown to worsen serum creatinine level (by 12%) compared to rasburicase, which improved creatinine level (by 31%).

Where rasburicase is available, it is the recommended solution over the use of allopurinol in patients with high risk of or clinically established tumour lysis syndrome

[DOI: 10.1056/NEJMr0904569](https://doi.org/10.1056/NEJMr0904569)

A 68-year-old woman is recovering from an elective knee replacement surgery for osteoarthritis. She has been receiving unfractionated heparin 5000 units twice a day. On day 10 she is breathless and computed tomographic pulmonary angiography shows bilateral pulmonary embolism. Laboratory investigation reveals a haemoglobin of $115-155 \text{ g/L}$ and platelet count of $45 \times 10^9 \text{ cells/L}$ ($150-450 \times 10^9 \text{ cells/L}$). Additional diagnostic investigation should be undertaken?

- A. Extractable nuclear antibodies
- B. Activated partial thromboplastin time
- C. Anti-phospholipid antibodies

D. Anti-platelet factor-4/heparin antibodies

E. Anti-thrombin II levels

Anti-Platelet Factor-4/Heparin antibodies

Heparin-induced thrombocytopenia (HIT) is caused by antibodies against complexes of platelet factor 4 (PF4) and heparin (Arepally and Ortel, 2006). Patients classically present with a low platelet count or a relative decrease of 50% or more from baseline. Thrombotic complications develop in approximately 20-50% of patients. Risk of thrombosis remains high for days to weeks after discontinuation of heparin, even after normalisation of platelet count. The incidence of HIT is 10 times higher in patients treated with unfractionated heparin compared to those receiving low-molecular-weight heparin. The incidence of HIT appears particularly high after orthopaedic surgery. Venous thromboses predominate in medical and orthopaedic patients, whereas arterial and venous thromboses occur at similar frequency in patients who have undergone cardiac or vascular surgery.

Laboratory tests play an important role in the diagnosis of HIT because of the challenges of clinical diagnosis. When HIT is suspected, testing for heparin-dependent antibodies is indicated with immunological assays, which identify circulating anti-PF4/heparin antibodies irrespective of their capacity to activate platelets or functional assays, which detect patient antibodies that induce heparin-dependent platelet activation or both. Immunological assays detect circulating IgG, IgM and IgA antibodies and are the first-line screening test. The major shortcoming of the immunological assays is limited specificity. False-positive results are common and may result from detection of non-pathogenic anti-PF4/heparin antibodies or anti-phospholipid antibodies against either PF4 or PF4-bound beta₂

glycoprotein I. Functional assays measure platelet activation and detect heparin-dependent antibodies capable of binding to and activating Fc receptors on platelets. The most extensively studied functional tests for HIT diagnosis are the platelet aggregation test and the heparin-induced platelet activation test.

erotonin release assay (SRA) and heparin-induced platelet activation assay (HIPA), Both tests are significantly more specific than existing immunoassays and are useful for confirming a positive immunological assay. Unfortunately, technical requirements restrict their use to a small number of reference laboratories, As such, they commonly do not provide results in the real time necessary to guide initial management.

[DOI: 10.1056/NEJMc052967](https://doi.org/10.1056/NEJMc052967)

30-year-old woman with known hypoparathyroidism and Addison disease has been found to have a mutation in the autoimmune regulator (AIRE) gene and has become progressively. What cause of anaemia should be considered?

- A. Haemolytic anaemia
 - B. Pure red cell aplasia
 - C. Iron-deficiency anaemia
 - D. Pernicious anaemia
 - E. Beta-thalassaemia minor
 - F. Sideroblastic anaemia
 - G. Anaemia of chronic disease
 - H. Sickle cell disease
-

Pernicious Anaemia

Mutations in an autoimmune-Suppressor gene (AIRE, for autoimmune regulator), which encodes a transcription factor, is responsible for autoimmune polyendocrine

Syndrom type I (Michels and Gottlieb, 2010). Individuals with any two of the following conditions- mucocutaneous candidiasis, hypoparathyroidism and Addison disease are likely to have AIRE mutations. Mutations to this gene cause many autoimmune diseases and affected patients are at risk for the development of multiple autoimmune diseases over time, including type 1 diabetes, hypothyroidism, pernicious anaemia, alopecia, vitiligo, hepatitis, ovarian atrophy and keratitis.

<https://doi.org/10.1038/nrendo.2010.40>